OncoMatch/Clinical Trials/NCT06604715
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Is NCT06604715 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JNJ-87562761 for relapsed or refractory multiple myeloma.
Treatment: JNJ-87562761 — The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Must have had prior therapy including a proteasome inhibitor
Must have received: immunomodulatory agent
Must have had prior therapy including an immunomodulatory agent
Must have received: anti-CD38 therapy
Must have had prior therapy including anti-CD38 therapy
Cannot have received: allogeneic transplant
Prior allogeneic transplant within 6 months before the start of study treatment administration
Cannot have received: autologous transplant
autologous transplant within 12 weeks before the start of study treatment administration
Cannot have received: targeted therapy
Targeted therapy ... within 21 days
Cannot have received: epigenetic therapy
epigenetic therapy ... within 21 days
Cannot have received: monoclonal antibody treatment
monoclonal antibody treatment ... within 21 days
Cannot have received: investigational drug
treatment with an investigational drug ... within 21 days
Cannot have received: invasive investigational medical device
treatment with an invasive investigational medical device ... within 21 days
Cannot have received: conventional chemotherapy
conventional chemotherapy within 21 days
Cannot have received: gene-modified adoptive cell therapy
gene-modified adoptive cell therapy ... within 3 months
Cannot have received: anti-CD38 therapy
treatment with anti-CD38 directed therapies within 3 months
Cannot have received: proteasome inhibitor
proteasome inhibitor [PI] therapy ... within 14 days
Cannot have received: radiation therapy
radiotherapy within 14 days
Cannot have received: immunomodulatory drug (IMiD) agent
immunomodulatory drug (IMiD) agent therapy within 7 days
Cannot have received: corticosteroids (prednisone)
Received a cumulative dose of corticosteroids equivalent to greater than or equal to (>=) 140 mg of prednisone within the 14-day period before the start of study treatment administration
Lab requirements
Kidney function
egfr > 30 ml/min/1.73 m^2 computed per 2021 ckd-epi creatinine equation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify